What people use when they have cancer and want to get well with alternative treatment

T/Tn antigens Neo-Springer Vaccine

Since the early 1970’s; using a various biochemical tests, immunologist Goerg Springer M.D. detected the T and Tn antigens in over 90% of all cancers. The less aggressive cancers (meaning they are well differentiated) produce higher proportion of the T antigen, while the Tn antigen predominates in more aggressive cancers (meaning they are poorly differentiated).

The overall concentrations of the T and Tn antigens correlate specifically with the aggressiveness of the Cancer.

Carcinoma cell (cancer cells) are cover with Sialic acid (which also serves as a carcinoma marker for diagnostic purposes) and this helps hide the cancer from the immune system. Sialic acid is not particular immunogenic.

T/Tn antigens (Neo-Springer Vaccine) are covalently attach to immunogenes in order to induce and immune response. The body then goes after the cancer With Vengeance.

If the cancer is large it may overwhelm any vaccine, so we often use the vaccine in conjunction with other non-immunosuppressive treatments to stop the grow of the tumor.

In 1974, Dr. Georg Springer had his first opportunity to test his experimental Vaccine when his wife, Heather Bligh, developed Breast cancer and was told she had only a year to live. After receiving the T/Tn Vaccine (Springer Vaccine), however she lived a full 6 years.

Springer had some advantages that other pioneers might envy. He funds his laboratory in part with his own inheritance from the famous German

Publishing company, Springer-Verlag. The Chicago researcher and his work were the focus of a laudatory, 11-page article in Life devoted to Breast cancer in Life magazine (5/94) “Springer results are startling” Life concluded.

Neo-Springer’s (T/Tn antigen) Vaccine is based on classical immunology. Antigens are substances that elicit an immune response. T/Tn antigens are protein and sugar substances that occur in all healthy non-cancerous cells. But are found there only in a masked condition. The T/Tn antigen pops to the surface of cells as soon as they become malignant. Springer’s method is an active, specific vaccination, which stimulates the immune system to fight against the cancer

” All human cancers differ from their parental healthy cells in the fine architecture of their cell surfaces” said Prof. Georg Springer, this is a result of the cancer cell’s incomplete assembly of normal cell membrane structures.

The body’s defense system naturally wants to fight against these incomplete abnormal structures the way it would invading viruses and microbes, because it recognizes them as something foreign, but it needs help, which the T/Tn antigen injections provide.

Prof. Springer wrote:

Aberrant Glycosylation is a hallmark in cancer cells. The blood precursors T (Thomsen-Friedenreich) and the Tn epitopes are shielded in healthy and benign-diseased tissues but uncovered in aproximately 90% of the carcinomas. T and Tn glycoproteins are specific, autoimmunogenic pancarcinoma antigens. These antigens may be also found in neoplasic blood cells (and LTV-II infected T lymphocytes).

T and Tn epitopes are cell and tissue adhesion molecules, essential in invasion by and metastasis of carcinoma, which includes adherent and proliferative phases. These properties are then delineated next, followed by consideration of pathophysiological and clinical aspects of these antigens. Everyone has “preexisting” anticarcinoma anti-Tn and anti-T antibodies, induced predominately by the intestinal flora, while cellular immune responses to T and Tn epitopes are evoked only by carcinomas and some lymphomas.

Carcinoma dedifferentiation leading to predominance of Tn over the T epitopes is described, as is the role of Tn and T epitopes in very early, including preclinical, carcinoma detection.

These findings open a novel window for both curative approaches and pathophysiological studies. The autoimmunogenicity of carcinoma T/Tn antigen led us more than two decades ago to begin intradermal vaccination of patients with advanced breast carcinoma of stages IV IIb, predominately after modified radical mastectomy and sometimes lumpectomy plus axillary dissection always followed by adjuvant radio/chemotherapy.

The original vaccine contained group “O” red blood membrane derived, HLA- free T/Tn antigen, and additional adjuvants

The modern vaccine has no human tissue or microorganism- derived components this have been replace by synthesized antigens thus precluding any possibility of contamination by unwanted virus or mycoplama bacteria.

http://www.sdiegoclinic.com